Aquapharm® is a leading marine biotechnology company pioneering the discovery and development of novel biochemistry isolated from the under explored biological diversity of marine microbes.
Their core focus is to develop novel antibiotics to treat Gram negative and Gram positive infections e.g. Pseudomonas aeruginosa, Acinetobacter, penicillin resistant Streptococci pneumoniae (PRSP), MRSA, & VRE and to isolate novel marine natural products for pharmaceutical applications. In addition, Aquapharm® has discovery activities in consumer / personal healthcare, nutrition and biocatalysis.
Through the application of proprietary fermentation 'stress / screening' technology to its microbial library, Aquapharm® induces the production of biologically active compounds from micro-organisms that are not produced under traditional fermentation conditions.
The Company has a number of antibiotic drug candidates with the lead anti-Gram positive candidate currently in pre-clinical development. Aquapharm® has also enjoyed considerable success in the discovery of a number of leads effective against Gram negative bacteria .
Additionally, the Company has a strong discovery pipeline of new anti-oxidants, anti-inflammatories (NF-kB suppression) and biocatalysts generated from its microbial library.